|Bid||16.00 x 200|
|Ask||28.00 x 400|
|Day's Range||23.02 - 23.50|
|52 Week Range||13.60 - 29.60|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 2, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.78|
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding ACOR totaled $491 million.
Acorda Therapeutics, Inc. will present new data for INBRIJA during four oral platform presentations at the upcoming American Academy of Neurology Annual Meeting in Los Angeles, taking place April 21–27, 2018.
Regenxbio (RGNX) is a clinical-stage biotechnology company focused on developing gene therapy product candidates to address genetic defects. The company’s product candidate RGX-314 is designed for the treatment of wet age-related macular degeneration (or wet AMD), which is a leading cause of total and partial vision loss in the US, Europe, and Japan. The other promising product candidate in Regenxbio’s pipeline is RGX-501 for the treatment of homozygous familial hypercholesterolemia (or HoFH).
In fiscal 2017, Acorda Therapeutics (ACOR) generated $96.5 million from operating activities, compared with $35.3 million in fiscal 2016. Despite the significant growth of its net loss in fiscal 2017, the company generated positive operating cash flow, mainly due to $296.7 million in asset impairment charges and a $40.6 million change in contingent consideration obligations.
Enanta Pharmaceuticals (ENTA) is a biotechnology company with a chemistry-driven approach. Enanta Pharmaceuticals discovered glecaprevir, a protease inhibitor for the treatment of chronic hepatitis C virus (or HCV). Enanta’s second protease inhibitor under its collaboration with AbbVie is marketed under the tradename Viekera Pak under AbbVie’s initial DAA regimens for the treatment of chronic HCV.
Acorda Therapeutics (ACOR), a biopharmaceutical company, develops therapies for neurological disorders. Of the ten analysts covering Acorda Therapeutics in April 2018, three have recommended “buy,” six have recommended “hold,” and one has recommended “sell.” Their mean rating for the stock is 2.8, and their target price is $24.78. Of the 20 analysts covering Intercept Pharmaceuticals (ICPT) in April 2018, ten have recommended “buy” or a higher rating, seven have recommended “hold,” and three have recommended “sell.” The mean rating for the stock is 2.5, and its target price is $110.91.
FibroGen (FGEN) is a biopharmaceutical company involved in the discovery and development of first-in-class therapeutics. The drug is in Phase 3 of development for the treatment of anemia in chronic kidney disease. The company has adopted a global approach to the development and commercialization of its product candidates.
Intercept Pharmaceuticals (ICPT) is a biopharmaceutical company focused on developing and commercializing novel therapeutics for the treatment of viral, progressive liver diseases utilizing its proprietary bile acid chemistry. Of the 20 analysts covering Intercept Pharmaceuticals in April 2018, ten of them have given the stock a “buy” or higher rating. Seven analysts have given it a “hold,” and three have given it a “sell.” The mean rating for the stock is 2.5 with a target price of $110.91.
Acorda Therapeutics (ACOR) is seeking approval of its Parkinson's disease candidate, Inbrija, in Europe for the treatment of symptoms of OFF periods.
Acorda Therapeutics, Inc. today announced that it has submitted a Marketing Authorization Application to the European Medicines Agency for INBRIJA. Acorda is seeking marketing approval in the European Union for INBRIJA, an investigational inhaled levodopa treatment for symptoms of OFF periods in people with Parkinson’s disease taking a carbidopa/levodopa regimen.
Acorda Therapeutics, Inc. today unveiled the “Live Well. Do Tell.” initiative for the Parkinson’s disease community. Its goal is to encourage the community to improve conversations about Parkinson’s symptoms among the circle of care, including people with Parkinson’s , care partners, advocacy and healthcare professionals.
Acorda Therapeutics, Inc. announced that Andrew Hindman, Acorda’s Chief Business Development Officer, will present at the Oppenheimer Healthcare Conference on Tuesday, March 20 at 11:30am.
Acorda Therapeutics, Inc. announced that Ron Cohen, M.D., Acorda's President and CEO, will present at the Cowen and Company 38th Annual Health Care Conference on Tuesday, March 13 at 10:00am EST.
Stock Monitor: Galapagos Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 02, 2018 / Active-Investors.com has just released a free research report on Acorda Therapeutics, Inc. (NASDAQ: ACOR ) ("Acorda"). ...
Acorda Therapeutics Inc (NASDAQ:ACOR) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
How worried should investors be about Celgene's FDA issues? Very, a review of 17 years of biotech history says.
Acorda Therapeutics, Inc. today announced that it has entered into a cooperation agreement with Scopia Capital Management LP.